Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-06-24
2008-06-24
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S386000, C514S408000, C514S410000, C514S416000, C514S533000, C514S642000, C514S659000
Reexamination Certificate
active
07390821
ABSTRACT:
The present invention provides methods of reducing angiogenesis in an individual. The methods generally involve administering to the individual an effective amount of a nicotinic acetyl choline receptor antagonist. The methods are useful to treat conditions associated with or resulting from angiogenesis, particularly pathological angiogenesis. The invention further provides methods of treating a condition associated with or resulting from angiogenesis.
REFERENCES:
patent: 4503038 (1985-03-01), Banda et al.
patent: 4749686 (1988-06-01), Hintze
patent: 4966890 (1990-10-01), Gillespie
patent: 5069904 (1991-12-01), Masterson
patent: 5318957 (1994-06-01), Cid et al.
patent: 5686448 (1997-11-01), Baldone
patent: 5820583 (1998-10-01), Demopulos et al.
patent: 5932545 (1999-08-01), Henkin et al.
patent: 6034079 (2000-03-01), Sanberg et al.
patent: 6121289 (2000-09-01), Houdi
patent: 6261279 (2001-07-01), Demopulos et al.
patent: 6417205 (2002-07-01), Cooke et al.
patent: 6610713 (2003-08-01), Tracey
patent: 6734215 (2004-05-01), Shytle et al.
patent: 6838471 (2005-01-01), Tracey
patent: 7045534 (2006-05-01), Cooke et al.
patent: 2002/0016344 (2002-02-01), Tracey
patent: 2002/0016370 (2002-02-01), Shytle et al.
patent: 2002/0016371 (2002-02-01), Shytle et al.
patent: 2002/0028798 (2002-03-01), Demopulos et al.
patent: 2002/0054896 (2002-05-01), Studin
patent: 2003/0087962 (2003-05-01), Demopulos et al.
patent: 2003/0096807 (2003-05-01), Demopulos et al.
patent: 2003/0096831 (2003-05-01), Stone et al.
patent: 2003/0130165 (2003-07-01), Reitz et al.
patent: 2003/0158112 (2003-08-01), Campochiaro
patent: 2003/0235589 (2003-12-01), Demopulos et al.
patent: 2004/0044083 (2004-03-01), Shytle et al.
patent: 2004/0132737 (2004-07-01), Cormier et al.
patent: 2004/0204355 (2004-10-01), Tracey et al.
patent: 2005/0021092 (2005-01-01), Yun et al.
patent: 2005/0075702 (2005-04-01), Shafer
patent: WO 00/35279 (2000-06-01), None
patent: WO 00/35279 (2000-06-01), None
patent: WO 00/35280 (2000-06-01), None
patent: WO 01/08684 (2001-02-01), None
Hannan, Robert L. et al. “Endothelial cells synthesize basic fibroblast growth factor and transforming growth factor beta”, Growth Factors, 1998, vol. 1, pp. 7-17.
Edelmen, Elazer R. et al.“Basic Fibroblast Growth Factor Enhances the Coupling of Intimal Hyperplasia and Proliferation of Vasa Vasorum in Injured Rat Arteries”, J. Clin. Invest., vol. 89, Feb. 1992, pp. 465-473.
Ribatti, Domenico et al. “Human Neuroblastoma Cells Produce Extracellular Matrix-Degrading Enzymes, Induce Endothelial Cell Proliferation and are Angiogenic In Vivo”, Int. J. Cancer: 77, 449-454 (1998).
Hyman, Ph.D., Leslie et al. “Hypertension, Cardiovascular Disease, and Age-Related Macular Degeneration” Arch Opthamol, vol. 118, Mar. 2000.
Cancer, Principles & Practice of Oncology, 6thed. Published by Lippiincott Williams & Wilkins (PA), 2001 pp. 143-145, 510.
Harrison's Principles of Internal Medicine, vol. 2, Isselbacher et al. eds., published 1994 by McGraw-Hill, Inc. (NY), pp. 1994-1995.
L.E. Chavez-Noriega et al. “Characterization of the recombinant human neuronal nicotinic acetylcholine receptors alpha3beta2 and alpha4beta2 stably expressed in HEK293 cells” Neuropharmacology, date unavailable.
B.T. Hawkins et al. “Smoking and ischemic stroke: a role for nicotine?” Trends in Pharmacological Sciences, vol. 23, No. 2, Feb. 1, 2002, pp. 78-82.
Schuller et al. (1989)Carcinogenesis10:1753-1755.
Maneckjee et al. (1994)Cell Growth Differ. 5:1033-1040.
Hong et al. (1995)J. Pharm. Sci. 84:65-70.
Schuller et al. (1989)Biochem. Pharmacol. 38:3439-3442.
Yancopoulos et al. (1998)Cell93:661-4.
Folkman et al. (1996)Cell87;1153-5.
Hanahan et al. (1996)Cell86:353-64.
Carmeliet et al. (2000)Nature407:249-257.
Folkman (1995)Nat Med1:27-31.
Heeschen et al. (2001)Nat Med7:833-837.
Grando et al. (1995)J Invest Dermatol105:774-781.
Macklin et al. (1998)Pharmacol Exp Ther287:435-439.
Wessler et al. (1999)Clin Exp Pharmacol Physiol26:198-205.
Kawashima et al. (1989)Neurosci Lett104:336-339.
Kawashima et al. (1990)Neurosci Lett119:156-158.
Kureishi et al. (2000)Nat Med6:1004-1010.
Jang et al. (2000)Circulation102:1414-1419.
Couffinhal et al. (1998)Am J Pathol152:1667-1679.
Lagasse and Weissman (1996)J Immunol Methods197:139-150.
Villablanca (1998)J Appl Physiol84:2089-2098.
Tarroni, P. et al. “Neuronal-type nicotinic receptors in human neorblstoma and small-cell lung carcinoma cell lines” FEBS Lett., 312: 66-70, 1992.
Cunningham, J.M. et al., Acetycholine receptors in small cell carcinomas, J. Neurochem., 45: 159-167, 1985.
Quik, M. et al., a-Bungaroxotin blocks the nicotinic receptor mediated increase in cell number in a neuroendocrine cell line. Brain Res., 655: 161-167, 1994.
Schuller et al. Nicotine, acetylcholine and bombesin are trophic growth factors in neuroendocrine cell line. Brain res., 655: 161-167, 1994.
Fucile et al. “Cholinergic stimulation of human micro-cytoma cell line H69” Biochem. Biophys. Res. Commun., 230: 501-504, 1997.
Novak et al., “Nicotine effects of proliferation and the bombesin-like peptide autorcine system in human small cell ling carcinoma SHP77 cells in culture” Lung Cancer, 29: 1-20, 2000.
Codignola, A., et al. “Serotonin release and cell profliferation are under the control of a-bungarotoxin-sensitive nicotinic receptors in small-cell lung carcinoma cell lines” FEBS Lett., 342:286-290, 1990.
Williams, C.L. and Lennon, V.A. Activation of M3 muscarinic acetylcholine receptors inhibits voltage-dependent calcium influx in small cell lung carcinoma cell. J. Biol. Chem., 265: 1443-1447, 1990.
Maneckjee, R. and Minna J.D., Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl. Acad. Sci. USA, 87: 3294-3298, date unavailable.
Song et al., Acetylcholine is Synthesized by and Acts as an Autocrine Growth Factor for Small Cell Lung Carcinoma, Cancer Research 63, 214-221, Jan. 1, 2003.
Heeschen, C. et al. “A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors”, Journal of Clinical Investigation, New York, NY, US, vol. 110, No. 4, Aug. 2002, pp. 527-536.
Heeschen C. et al. “Nicotine Stimulates Angiogenesis and Promotes Tumor Growth and Atherosclerosis” Nature Medicine, Nature Publishing, CO, US, Col. 7, No. 7, Jul. 2001, pp. 833-839.
A.C. Villablanca “Nicotine Stimulates DNA Synthesis and Proliferation in Vascular Endothelial Cells in Vitro” Journal of Applied Physiology, vol. 84, No. 6, 1998, pp. 2089-2098.
Maneckjee, R. et al., “Effects of opioids and nicotine on apoptosis in human lung cancer cells” Analgesia (1995) 1 (4-6), 548-52.
Jacobi J. et al. “Nicotine Accelerates Angiogenesis and Wound Healing in Genetically Diabetic Mice” in The American Journal of Pathology. Jul. 2002 vol. 161, nr 1, pp. 97-104.
Takamura et al. “Effects of Various Chemical Compounds of Ehrlich Ascites Tumor Cells in a Maintenance Medium”, 1989, vol. 14, Nr. 2, pp. 241-245.
Stone et al., “Effects of Nicotinic Antagonists on Ocular Growth and Experimental Myopia”, Investigative Ophthalmology & Visual Science, Mar. 2001, vol. 42, No. 3, pp. 557-565.
Stone et al., “Associations between Childhood Refraction and Parental Smoking”, Investigative Ophthalmology & Visual Science, Oct. 2006, vol. 47, No. 10, pp. 4277-4287.
Chavez-Noriega et al., “Characterization of the recombinant human neuronal nicotinic acetylcholine receptors α3β2 and α4β2 stably expressed in HEK293 cells”, (2000), Neuropharmacology, vol. 39, pp. 2543-2560, XP-002315250.
Hawkins et al., Smoking and ischemic stroke: a role for nicotine?: (2002), Trends in Pharmacological Sciences, vol. 23, No. 2, pp. 78-82, XP-002315249.
Heeschen et al., “Nicotine stimulates angiogensis and promotes tumor growth and atherosclerosis”, (2001), Nature Medicine, vol. 7, No. 7, p
Cooke John
Heeschen Christopher
Weis Michael
Borden Paula A.
Bozicevic Field & Francis LLP
Francis Carol L.
Henley III Raymond J.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Methods of reducing angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of reducing angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of reducing angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2813564